Interim reports

Lundbeck achieved an exceptionally strong financial performance in Q2 2008 with revenue continuing to grow and climbing 12% on the year-earlier period. Exclusive of a DKK 481 million writedown of the value of the Flurizan^® rights, profit from operations rose 22% relative to the same period of last year. Lundbeck retains its financial guidance for 2008, which now includes a reduction of escitalopram inventories to Lundbeck’s US partner Forest Laboratories, Inc. during H2 2008.

Revenue, earnings and investments

• Revenue: DKK 2,938 million (+12% and +14% at CER)
• Profit from operations (EBIT) incl. one-off items: DKK 363 million (-48%)
• Profit from operations (EBIT) excl. one-off items: DKK 844 million (+22%)
• Investments: DKK 88 million (excl. in-licensing and milestone payments)

Revenue by regions and products

• Europe: DKK 1,574 million (+15% and +17% at CER)
• International Markets: DKK 621 million (+13% and +21% at CER)
• USA: DKK 692 million (+8% and +7% at CER)
  
• Cipralex^®: DKK 1,234 million (+20% and +24% at CER)
• Lexapro^®: DKK 692 million (+8% and +7% at CER)
• Ebixa^®: DKK 467 million (+14% and +16% at CER)
• Azilect^®: DKK 63 million (+58% and +60% at CER)

 

You can download the free Adobe Acrobat Reader plug-in at: www.adobe.com

• Q2 2008 (226 Kb)
• Q1 2008 (196 Kb) 
• Q3 2007 (255 Kb)
• Q2 2007 (224 Kb)
• Q1 2007 (220 Kb)
• Q3 2006 (501 Kb)
• Q2 2006 (262 Kb)
• Q1 2006 (247 Kb)
• Q3 2005 (222 Kb)
• Q2 2005 (530 Kb)
• Q1 2005 (291 Kb)
• Q3 2004 (283Kb)
• Q2 2004 (2Mb)
• Q1 2004 (200 Kb)
• Q3 2003 (199Kb)
• Q2 2003 (1Mb)
• Q1 2003 (215 Kb)
• Q3 2002 (219 Kb)
• Q2 2002 (1.2 Mb)
• Q1 2002 (88 Kb)
• Q3 2001 (158 Kb)
• Q2 2001 (90 Kb)
• Q1 2001 (62 Kb)
• Q3 2000 (68 Kb)
• Q2 2000 (168 Kb)
• Q1 2000 (40 Kb)
• Q4 1999 (89 Kb)
• Q3 1999 (23 Kb)
• Q2 1999 (401 Kb)